biotech / news / / The Boston Globe
The Supreme Court turned away appeals from six pharmaceutical companies.
The Supreme Court declined to hear pharmaceutical companies' constitutional challenges to Medicare drug price negotiations.
KEY POINTS
- Novo Nordisk's Ozempic and Wegovy will face a 71 percent Medicare discount starting in 2027.
- The program is expected to generate $12 billion in Medicare savings on 15 drugs compared to 2024 prices.
- Federal appeals courts have so far uniformly upheld the legality of the Medicare price negotiation program.
- Drugmakers argue they must accept the government's price or leave half the US market, an unrealistic choice.
COMPANIES
Summarized by Newsio from The Boston Globe. How we summarize →